



## Dr Vivek Venkatramani

M.Ch. (Urology), M.S. (General Surgery) Fellowship in Urologic Oncology (Miami, USA) 15+ Years Experience

Dr Vivek Venkatramani is a top Oncologist in Mumbai at Apollo Hospitals Navi Mumbai . Book appointment online with Dr Vivek Venkatramani at Ask Apollo.

### Hospitals

Apollo Hospitals, Mumbai ,

Doctor's Working  
Weekdays  
Wed - Fri

Doctor's Working  
Hours  
10:00 - 16:00

Phone Icon  
Call Now

Calendar Icon  
Book Appointment

## Overview

Dr. Vivek Venkatramani is a renowned Uro Oncologist based in Mumbai, Maharashtra, with over 15 years of specialized experience in the field of urology and urologic oncology. He holds advanced qualifications including an M.Ch. in Urology and an M.S. in General Surgery, complemented by a Fellowship in Urologic Oncology from Miami, USA. With a commitment to excellence in patient care and groundbreaking research, Dr. Venkatramani has distinguished himself not only as a clinician but also as an accomplished scholar. His contributions to urology have been recognized with numerous prestigious awards, including the Best Video Prize at the Annual Conference of the West Zone of the Urological Society of India in 2022 and the Best Poster award at the Annual Conference of the American Urological Association in 2020. He was also honored with the Dr. Seetharaman Memorial Best Essay prize in 2014 for his insightful work on the future of urology. Dr. Venkatramani's academic prowess earned him the Shaliwahan Singh Rawal Gold Medal for Best Student in Urology during his residency, as well as the C.K.P. Menon Best Paper award for his significant research in bladder tumour treatment methods at the Urological Society of India conference in 2013. Fluent in Marathi, English, and Hindi, he effectively communicates with diverse patient populations, ensuring that each individual receives personalized and compassionate care. His dedication to advancing urologic oncology, combined with his exceptional clinical skills, makes Dr. Vivek

Venkatramani a leader in his field and a trusted ally for patients facing complex urological challenges.

## Experience

*Visiting Consultant Uro-Oncologist and Robotic Surgeon*

*August 2018 - present*

**Nanavati Superspeciality Hospital,**

Mumbai,

India.

*Visiting Consultant Urologist and Uro-Oncologist*

*February 2022 - present*

**Saifee Hospital,**

**Lilavati Hospital and Research Center**

**S.L. Raheja Hospital**

Mumbai,

India.

*Voluntary Visiting Assistant Professor of Urology*

*July 2018 - present*

**University of Miami Miller School of Medicine,**

Miami, FL, United States

## Membership

- American Urological Association.
- Urological Society of India.
- Indian Medical Association.
- West Zone – Urological Society of India.
- Associate Member, Association of Southern Urologists.
- Mumbai Urologic Society

## Awards

- **Best Video Prize**

*Robotic radical prostatectomy with extravesical bladder diverticulectomy: Video of a challenging case*

– West Zone USI Annual Conference, Nashik, 2022

- **Best Poster Award**

*Predictors of readmission rates following robotic and open radical cystectomy: An analysis from the RAZOR trial*

– Moderated Poster Session, AUA Annual Conference, Virtual AUA, 2020

- **Dr. Seetharaman Memorial Best Essay Prize**

*“Urovision 2020: The Future of Urology”*

– USICON, New Delhi, 2014

- **Shaliwahan Singh Rawal Gold Medal**

For Best Student in Urology – awarded by CMC Vellore for academic excellence during residency and M.Ch. exams

- **C.K.P. Menon Best Paper Award**

*Monopolar vs. Bipolar TURBT: A Randomized Controlled Trial*

– USICON, Pune, 2013

- **Selected for European Union Residents Education Program (EUREP)**

– Prague, August 31 – September 5, 2012

- **Best Paper Presentation**

*Exstrophy-epispadias complex – Adult presentation: An audit*

– South Zone USICON, Mahabalipuram, 2011

- **Best Poster Award**

*Dental Caries in Thalassemic Children (1–12 years)*

– Research Society, B J Medical College Annual Conference, 2004

- **Winner – Undergraduate Open Quiz**

– 31st Annual Conference of the Research Society of B J Medical College, 2004

- **Academic Distinctions – Final M.B.B.S**

– Paediatrics, Obstetrics & Gynaecology

– Ranked First in College in Paediatrics

- **Academic Distinctions – 3rd M.B.B.S. (Part 1)**

– ENT and Ophthalmology

- **Winner – Inter College PSM Quiz**

– Armed Forces Medical College, Pune (World Health Day), 2002

- **Winner – Maharashtra State Level PSM Quiz**  
– November 2002
- **Academic Distinctions – 2nd M.B.B.S.**  
– Pathology, Microbiology, Pharmacology
- **Academic Distinctions – 1st M.B.B.S.**  
– Anatomy, Physiology, Biochemistry
- **Best Speaker Prize**  
– Seminar on *Adrenal Cortical Hormones*, Physiology Dept., B J Medical College

## Research and Publication

### A) Reviewer

1. Editorial Board, Indian Journal of Urology
2. Reviewer, Journal of Urology,
3. Reviewer. Indian Journal of Urology
4. Reviewer, Journal of Endourology
5. Reviewer, Asian Journal of Urology

### B) Journal Articles

1. Comparison of Robot-Assisted and Open Radical Cystectomy in Recovery of Patient-Reported and Performance-Related Measures of Independence: A Secondary Analysis of a Randomized Clinical Trial. **Venkatramani V**, Reis IM, Gonzalgo ML, Castle EP, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Parekh DJ. *JAMA Netw Open*. 2022 Feb 1;5(2):e2148329. PMID: 35171260
1. Expert survey on management of prostate cancer in India: Real-world insights into practice patterns. Bakshi G, Tongaonkar H, Addla S, Menon S, **Venkatramani V**, Murthy V et al. *Indian J Cancer*. 2022 49:S19-S45. PMID: 35343189
1. Focal therapy for localized prostate cancer - Current status. Atluri S, Mouzannar A, **Venkatramani V**, Parekh DJ, Nahar B. *Indian J Urol*. 2022 38:7-14. PMID: 35136289

1. Surgery for Bladder and Upper Tract Urothelial Cancer. **Venkatramani V**, Parekh DJ. *Hematol Oncol Clin North Am.* 2021 Jun;35(3):543-566. PMID: 33958150 .
1. Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy. Becerra MF, **Venkatramani V**, Reis IM, Soodana-Prakash N, Punnen S, Gonzalgo ML, Raolji S, Castle EP, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Parekh DJ. *J Urol.* 2020 Sep;204(3):450-459.PMID: 32271690.
1. Prospective Evaluation of Focal High Intensity Focused Ultrasound for Localized Prostate Cancer. Nahar B, Bhat A, Reis IM, Soodana-Prakash N, Becerra MF, Lopategui D, **Venkatramani V**, Patel R, Madhusoodanan V, Kryvenko ON, Ritch CR, Gonzalgo ML, Punnen S, Parekh DJ. *J Urol.* 2020 Sep;204(3):483-489.PMID: 32167866.
1. Corrigendum to "Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy". Bhat A, Nahar B, **Venkatramani V**, Banerjee I, Kryvenko ON, Parekh DJ. *Case Rep Urol.* 2019 Nov 20;2019:5734970. PMID: 31827970.
1. [Predictors of Recurrence, Progression-Free and Overall Survival Following Open Versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Follow-Up.](#) **Venkatramani V**, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, et al *J Urol.* 2020 Mar;203(3):522-529. PMID: 31549935
1. [Editorial comment on END-2019-0226-I-RE.R1.](#) **Venkatramani V**, Parekh D. *J Endourol.* 2019 2019 Dec;33(12):985. PMID: 3154449
1. [Validation of dominant and secondary sequence utilization in PI-RADS v2 for classifying prostatic lesions.](#) Soodana-Prakash N, Castillo RP, Reis IM, Stoyanova R, Kwon D, Velasquez MC, Nahar B, Kannabur P, Johnson TA, Swain SK, Ben-Yakar N, **Venkatramani V**, Ritch C, Satyanarayana R, Gonzalgo ML, Parekh DJ, Bittencourt L, Punnen S. *Can J Urol.* 2019; 26:9763-9768. PMID: 31180306
1. [Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy.](#) Bhat A, Nahar B, **Venkatramani V**, Banerjee I, Kryvenko ON, Parekh DJ. *Case Rep Urol.* 2019 Mar 14;2019:7102504. PMID: 31001447

1. Evidence trumps consensus. **Venkatramani V**, Parekh DJ; RAZOR trial investigators. *BJU Int.* 2019 Mar;123(3):374-375. PMID: 30821095.
1. Robot-assisted versus open cystectomy in the RAZOR trial - Authors' reply. Parekh DJ, **Venkatramani V**; RAZOR trial authors. *Lancet.* 2019 Feb 16;393(10172):645-646. PMID: 30782338
1. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (**RAZOR**): an open-label, randomised, phase 3, non-inferiority trial. Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, **Venkatramani V**, Soodana-Prakash N, Kendrick K, Smith JA Jr, Thompson IM. *Lancet.* 2018 Jun 23;391(10139):2525-2536. PMID: 29976469
1. A comparison of overall survival and perioperative outcomes between partial and radical nephrectomy for cT1b and cT2 renal cell carcinoma-Analysis of a national cancer registry. **Venkatramani V**, Koru-Sengul T, Miao F, Nahar B, Prakash NS, Swain S, Punnen S, Ritch C, Gonzalgo M, Parekh D. *Urol Oncol.* 2018 Mar;36(3):90.e9-90.e14. doi: 10.1016/j.urolonc.2017.11.008. Epub 2017 Dec 16. PubMed PMID: 29254672.
1. [Validation of dominant and secondary sequence utilization in PI-RADS v2 for classifying prostatic lesions.](#) Soodana-Prakash N, Castillo RP, Reis IM, Stoyanova R, Kwon D, Velasquez MC, Nahar B, Kannabur P, Johnson TA, Swain SK, Ben-Yakar N, **Venkatramani V**, Ritch C, Satyanarayana R, Gonzalgo ML, Parekh DJ, Bittencourt L, Punnen S. *Can J Urol.* 2019 Jun;26(3):9763-9768. PMID: 31180306.
1. [Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy.](#) Bhat A, Nahar B, **Venkatramani V**, Banerjee I, Kryvenko ON, Parekh DJ. *Case Rep Urol.* 2019 Mar 14;2019:7102504. doi: 10.1155/2019/7102504. eCollection 2019. PMID: 31001447
1. Perioperative outcomes and complication predictors associated with open and minimally invasive nephroureterectomy. Soodana-Prakash N, Balise R, Nahar B, **Venkatramani V**, Palmer J, Pavan N,

Johnson TA, Rai S, Satyanarayana R, Ritch C, Punnen S, Parekh DJ, Gonzalgo ML. *Can J Urol*. 2018 Aug;25(4):9395-9400. PMID: 30125518

1. Disparities in Hispanic/Latino and non-Hispanic Black men with low-risk prostate cancer and eligible for active surveillance: a population-based study. Katz JE, Chinea FM, Patel VN, Balise RR, **Venkatramani V**, Gonzalgo ML, Ritch C, Pollack A, Parekh DJ, Punnen S. *Prostate Cancer Prostatic Dis*. 2018 Jul 9. doi: 10.1038/s41391-018-0057-6. [Epub ahead of print]. PMID: 29988097
1. Trends in Utilization of Robotic and Open Partial Nephrectomy for Management of cT1 Renal Masses. Alameddine M, Koru-Sengul T, Moore KJ, Miao F, Sávio LF, Nahar B, Prakash NS, **Venkatramani V**, Jue JS, Punnen S, Parekh DJ, Ritch CR, Gonzalgo ML. *Eur Urol Focus*. 2018 Jan 8. pii: S2405-4569(17)30293-6. doi: 10.1016/j.euf.2017.12.006. [Epub ahead of print] PubMed PMID: 29325761.
1. Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy formuscle-invasive bladder cancer. Ritch CR, Balise R, Prakash NS, Alonzo D, Almengo K, Alameddine M, **Venkatramani V**, Punnen S, Parekh DJ, Gonzalgo ML. *BJU Int*. 2017 Dec 27. doi: 10.1111/bju.14109. [Epub ahead of print] PubMed PMID: 29281848.
1. Comparison of readmission and short-term mortality rates between different types of urinary diversion in patients undergoing radical cystectomy. Nahar B, Koru-Sengul T, Miao F, Prakash NS, **Venkatramani V**, Gauri A, Alonzo D, Alameddine M, Swain S, Punnen S, Ritch C, Parekh DJ, Gonzalgo ML. *World J Urol*. 2018 Mar;36(3):393-399. doi: 10.1007/s00345-017-2140-3. Epub 2017 Dec 11. PubMed PMID: 29230495.
1. Reclassification Rates of Patients Eligible for Active Surveillance After the Addition of Magnetic Resonance Imaging-Ultrasound Fusion Biopsy: An Analysis of 7 Widely Used Eligibility Criteria. Nahar B, Katims A, Barboza MP, Soodana Prakash N, **Venkatramani V**, Kava B, Satyanarayana R, Gonzalgo ML, Ritch CR, Parekh DJ, Punnen S. *Urology*. 2017 Dec;110:134-139. doi: 10.1016/j.urology.2017.08.016. Epub 2017 Aug 24. PubMed PMID: 28842208.
1. Current Status of Nephron-Sparing Surgery (NSS) in the Management of Renal Tumours. **Venkatramani V**, Swain S, Satyanarayana R, Parekh DJ. *Indian J Surg Oncol*. 2017 Jun;8(2):150-155. doi: 10.1007/s13193-016-0587-0. Epub 2017 Jan 30. Review. PubMed PMID: 28546710; PubMed Central PMCID: PMC5427030.

1. Imaging for the selection and monitoring of men on active surveillance for prostate cancer. Velasquez MC, Soodana-Prakash N, **Venkatramani V**, Nahar B, Punnen S. *Transl Androl Urol*. 2018 Apr;7(2):228-235. doi: 10.21037/tau.2017.08.13. Review. PMID: 29732281
1. Using microscope for onco-testicular sperm extraction for bilateral testis tumors. Carrasquillo R, Sávio LF, **Venkatramani V**, Parekh D, Ramasamy R. *Fertil Steril*. 2018 Apr;109(4):745. doi: 10.1016/j.fertnstert.2018.01.016. PMID: 29653719
1. Perioperative complications and postoperative outcomes of partial nephrectomy for renal cell carcinoma: Does indication matter? **Venkatramani V**, Kumar S, Chandrasingh J, Devasia A, Kekre NS. *Indian J Urol*. 2017 Apr-Jun;33(2):140-143. doi: 10.4103/0970-1591.203420. PubMed PMID: 28469302; PubMed Central PMCID: PMC5396402.
1. Re-examining Prostate-specific Antigen (PSA) Density: Defining the Optimal PSA Range and Patients for Using PSA Density to Predict Prostate Cancer Using Extended Template Biopsy. Jue JS, Barboza MP, Prakash NS, **Venkatramani V**, Sinha VR, Pavan N, Nahar B, Kanabur P, Ahdoot M, Dong Y, Satyanarayana R, Parekh DJ, Punnen S. *Urology*. 2017 Jul;105:123-128. doi: 10.1016/j.urology.2017.04.015. Epub2017 Apr 18. PubMed PMID: 28431993.
1. Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial. **Venkatramani V**, Panda A, Manojkumar R, Kekre NS. *J Urol*. 2014 Jun;191(6):1703-7. doi: 10.1016/j.juro.2013.12.004. Epub 2013 Dec 11. PubMed PMID: 24333244.
1. Re: Hussain AA et al. Reoperations following robot-assisted radical cystectomy: A decade of experience: Editorial Comment. **Venkatramani V**, Parekh DJ. *J Urol*. 2016 May;195(5):1375. doi: 10.1016/j.juro.2015.10.193. Epub 2016 Feb 4. Review. PubMed PMID: 26851996.
1. Urovision 2020: The future of urology. **Venkatramani V**. *Indian J Urol*. 2015 Apr-Jun;31(2):150-5. doi: 10.4103/0970-1591.152918. PubMed PMID: 25878422; PubMed Central PMCID: PMC4397557.
1. Bilateral ovarian metastases from ureteric urothelial cancer: Initial case report and distinguishing role of immunohistochemistry. **Venkatramani V**, Banerji JS, Manojkumar R. *Can Urol Assoc J*. 2015 Jan-Feb;9(1-2):E52-4. doi: 10.5489/cuaj.2374. PubMed PMID: 25624971; PubMed Central PMCID:



1. Is thrombocytosis a useful prognostic marker in renal cell carcinoma? Results of a single-center retrospective analysis. **Venkatramani V**, Panda A, Kekre NS. *Indian J Urol*. 2015 Jan-Mar;31(1):42-6. doi: 10.4103/0970-1591.145292. PubMed PMID: 25624575; PubMed Central PMCID: PMC4300571.
1. Exstrophy-epispadias complex presenting in adulthood: a single-center review of presentation, management, and outcomes. **Venkatramani V**, Chandrasingh J, Devasia A, Kekre NS. *Urology*. 2014 Nov;84(5):1243-7. doi: 10.1016/j.urology.2014.06.063. Epub 2014 Oct 24. PubMed PMID: 25443942.
1. Spontaneous perinephric hemorrhage (Wunderlich syndrome) secondary to polyarteritis nodosa: Computed tomography and angiographic findings. **Venkatramani V**, Banerji JS. *Indian J Urol*. 2014 Oct;30(4):452-3. doi: 10.4103/0970-1591.139585. PubMed PMID: 25378832; PubMed Central PMCID: PMC4220390.
1. Incidental detection of retroperitoneal lymphangi leiomyomatosis (LAM) - CT and MRI findings with relevance to the urologist. Phukan C, Prabhu S, **Venkatramani V**. *Int Braz J Urol*. 2014 Jul-Aug;40(4):574-5. doi: 10.1590/S1677-5538.IBJU.2014.04.19. PubMed PMID: 25251963.
1. Splenogonadal fusion: pathological features of a rare scrotal mass. Duhli N, **Venkatramani V**, Panda A, Manojkumar R. *Indian J Pathol Microbiol*. 2013 Oct-Dec;56(4):474-6. doi: 10.4103/0377-4929.125387. PubMed PMID: 24441256.
1. Urogenital fistulae in India: results of a retrospective analysis. **Venkatramani V**, Shanmugasundaram R, Kekre NS. *Female Pelvic Med Reconstr Surg*. 2014 Jan-Feb;20(1):14-8. doi: 10.1097/SPV.0000000000000040. PubMed PMID: 24368482.
1. Urethral duplication with unusual cause of bladder outlet obstruction. **Venkatramani V**, George AJ, Chandrasingh J, Panda A, Devasia A. *Indian J Urol*. 2016 Apr-Jun;32(2):156-8. doi: 10.4103/0970-1591.174780. PubMed PMID: 27127361; PubMed Central PMCID: PMC4831507.
1. [Emphysematous pyelonephritis in a renal transplant recipient--is it possible to salvage the graft?](#) **Vivek V**, Panda A, Devasia A. *Ann Transplant*. 2012; 17:138-41.

1. Visualization of male reproductive tract during urethrography: sequel of intense backpressure. **Venkatramani V**, Mukha RP. *ANZ J Surg.* 2015 May;85(5):393. doi: 10.1111/ans.12461. Epub 2013 Nov 20. PubMed PMID: 24252111.
1. Equivocal pelvi-ureteric junction obstruction manifesting in a renal transplant recipient. **Venkatramani V**, Mukha RP, Kekre NS *Indian J Urol.* 2012 Jul;28(3):350-2. doi: 10.4103/0970-1591.102727. PubMed PMID: 23204671; PubMed Central PMCID: PMC3507412.
1. Breast gangrene in an HIV-positive patient. **Venkatramani V**, Pillai S, Marathe S, Rege SA, Hardikar JV. *Ann R Coll Surg Engl.* 2009 Jul;91(5):W13-4. doi: 10.1308/147870809X401056. PubMed PMID: 19622255; PubMed Central PMCID: PMC2758440.
1. Can telemedicine reverse the brain drain? **Venkatramani V**, Roy D. *J R Soc Med.* 2006 Jan;99(1):5. PubMed PMID: 16388047; PubMed Central PMCID: PMC1325071.
1. Comparison of glomerular filtration rate (GFR) changes in radical nephrectomy versus nephron sparing surgery (NSS) for pT1 renal cell carcinoma (RCC). Phukan C, **Venkatramani V**, Banerji JS, Kekre NS, Devasia A. *Merit Research Journal of Medicine and Medical Sciences.* 2015; 3; published online.
1. Shock-wave lithotripsy for lower calyceal stones >1cm in size: Out-dated or still standard of care? Kekre NS, **Venkatramani V**. *Med-ej - Journal of TNMGRMU*, 2013; published online.
1. Is Paclitaxel-based chemotherapy the way forward in testicular cancer? **Venkatramani V**. *Indian J Urol* 2013; 29:268-9. (*Uroscan*)
1. Is it time to rethink maintenance Bacillus Calmette-Guerin? **Venkatramani V**. *Indian J Urol* 2012; 28:238-9. (*Uroscan*)
1. Audit on the success rate of vesico-vaginal fistulae repairs. **Venkatramani V**. *CMC journal* 2013; published online.
1. Parekh DJ, **Venkatramani V**. Assessing Treatment Response After Intravesical Bacillus Calmette–Guerin Induction Cycle: Are Routine Bladder Biopsies Necessary?. PracticeUpdate website. Available at: <https://www.practiceupdate.com/content/assessing-treatment-response-after-intravesical->

## B) Book Chapters

1. Robot-Assisted Radical Cystectomy versus Open Radical Cystectomy. (Chapter 59. **Venkatramani V**, Parekh DJ. *Robotics in Genitourinary Surgery, 2nd ed*, edited by Ashok K. Hemal, MD and Mani Menon, MD.
1. High Intensity Focused Ultrasound (HIFU) Options for High-Risk Prostate Cancer. Nahar B, **Venkatramani V** and Parekh DJ. *Prostate Cancer Clinical Scenarios* by Chang and Cookson - Springer International Publishing, in press.
1. Long term complications of Androgen Deprivation Therapy for Prostate Cancer and how to manage them. Nahar B, **Venkatramani V**, Barboza MP, Soodana-Prakash N, Punnen S. *AUA Update Series 2017*, Volume 36, Lesson 32: 311-322.

## Frequently Asked Questions

### 1. Where does Dr. VIVEK VENKATRAMANI practice?

Dr. VIVEK VENKATRAMANI currently practices at Apollo Hospitals Navi Mumbai, located in Mumbai.

### 2. Who is Dr. VIVEK VENKATRAMANI?

Dr. VIVEK VENKATRAMANI is a highly experienced Oncologist with 15 years of expertise in the field. He is known for providing exceptional patient care and advanced medical treatments. His areas of expertise include Chemotherapy, Radiation Therapy. He also treats conditions such as , Prostate cancer.

### 3. Why do patients choose Dr. VIVEK VENKATRAMANI?

Patients trust Dr. VIVEK VENKATRAMANI for his expertise, patient-centric approach, and commitment to providing the highest standard of care. He is well-versed in the latest medical advancements and ensures personalized treatment for every patient.

#### **4. What is Dr. VIVEK VENKATRAMANI's specialization?**

Dr. VIVEK VENKATRAMANI specializes in Oncology, with expertise in treatments for Chemotherapy, Radiation Therapy.

#### **5. What are Dr. VIVEK VENKATRAMANI's medical qualifications?**

Dr. VIVEK VENKATRAMANI holds prestigious qualifications, including M.Ch. (Urology) | M.S. (General Surgery) Fellowship in Urologic Oncology (Miami, USA).

#### **6. How many years of experience does Dr. VIVEK VENKATRAMANI have?**

Dr. VIVEK VENKATRAMANI has 15 years of experience in the medical field, treating various conditions related to Oncology.

#### **7. How can I book an appointment with Dr. VIVEK VENKATRAMANI?**

You can book an appointment with Dr. VIVEK VENKATRAMANI through: Online: Visit <https://www.apollohospitals.com/book-doctor-appointment/> to schedule an appointment.